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Monoclonal antibodies (mAb) complemented the ther-
apy of malignant lymphomas. Currently, mAb against
CD20 or CD52 are approved and CD22 or HLA-class-II
mAb are in clinical trials for the treatment for malignant
B-cell lymphomas. Mechanism of action in vivo is not yet
completely understood, but direct induction of apoptosis,
activation of complement, and Fc-receptor dependent
mechanisms including antibody-dependent-cellular-cyto-
toxicity (ADCC) seem to contribute to their clinical effi-
cacy. At the same time proteasome inhibitors (PI) were
developed as a novel class of anti-neoplastic agents. Their
proposed mechanism of action include inhibition of the
NFκB pathway by blocking the degradation of IκB in the
proteasome, overriding of Bcl-2 mediated resistance in
lymphoma cells and induction of apoptosis. MG262 (Z-
Leu-Leu-Leu- B(OH)2) is a PI belonging to the peptide
boronate class of PIs including the clinically successfull PI
Bortezomib (Velcade), which is approved as third line
treatment of multiple myeloma.
We have previously demonstrated that polymorphonu-
clear granulocytes (PMN) are potent effector cells mediat-
ing ADCC against a wide range of malignant B-cell
opsonized with HLA-class-II mAb. In the presence of sub-
optimal concentrations of HLA-class-II directed mAb F3.3
isolated PMN mediated modest amounts of cytotoxicity
in Cr-release assays, which were significantly enhanced in
the presence of the PI MG262 (31 ± 12%, 15 ± 3%, 68 ±
8% specific lysis for F3.3, MG262 and F3.3+MG262). In
the absence of PMN as effector cells mAb F3.3 at the sub-
optimal concentration of 0.01 µg/mL elicited no signifi-
cant cytotoxicity, whereas MG262 mediated
concentration dependent target cell death up to 15 ± 3%
specific lysis at 2.5 µM.
However, whereas PMN mediated significant lysis with
HLA-class-II mAb, no significant lysis was observed with
CD20, CD22 or CD52 directed antibodies. The promising
results with the combination of HLA-class-II mAb and PI
encourage us to extend our experiments to the combina-
tion of PIs, including bortezomib, with Rituximab
(CD20), Epratzumab (CD22) or Alemtuzumab (CD52)
mAb mediated cytotoxicity using PMN as effector cells.
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